CC
EPZM

CQS Cayman’s Epizyme, Inc EPZM Stock Holding History

CQS Cayman’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-614,300
Closed -$9.28M – 117
2017
Q2 		$9.28M Hold
614,300
– – 0.64% 50
2017
Q1 		$10.5M Sell
614,300
-20,000
-3% -$266K 0.8% 45
2016
Q4 		$7.67M Hold
634,300
– – 0.61% 49
2016
Q3 		$6.24M Sell
634,300
-700
-0.1% -$6.39K 0.52% 43
2016
Q2 		$6.5M Buy
+635,000
New +$7.08M 0.57% 49

Other funds holding EPZM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

CQS Cayman's EPZM Position: Q3 2017 in Review

CQS Cayman sold out of Epizyme, Inc (EPZM) in Q3 2017, closing a stake of 614,300 shares — an estimated $9.28M sold.

CQS Cayman first reported a position in EPZM in Q2 2016 and held it in 5 quarters. The position peaked at $10.5M in Q1 2017. 104 funds tracked by Wall St. Rank hold EPZM as of Q3 2017.

  • CQS Cayman reported no remaining Epizyme, Inc position as of Q3 2017 after selling out during the quarter.
  • CQS Cayman sold 614,300 Epizyme, Inc shares in Q3 2017, an estimated $9.28M.
  • CQS Cayman first reported a position in Epizyme, Inc in Q2 2016 and held it in 5 quarters.
  • CQS Cayman's Epizyme, Inc position peaked at $10.5M in Q1 2017.
  • 104 funds tracked by Wall St. Rank held Epizyme, Inc as of Q3 2017.

Based on CQS Cayman's 13F filing for Q3 2017, filed 15 Nov 2017.